Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Chapman Christopher C JR	2. Issuer Name and Ticker or Trading Symbol MyMD Pharmaceuticals, Inc. [ MYMD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President, Chief Med. Officer
(Last) (First) (Middle) 1185 AVENUE OF THE AMERICAS, 3RD FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 4/16/2021
(Street) NEW YORK,, NY 10036 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	4/16/2021		A		96475	A	⁽¹⁾	96475	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.5913	4/16/2021		A		38590		⁽³⁾	4/16/2023	Common Stock	38590	⁽²⁾	38590	D
Stock Option (Right to Buy)	$2.5913	4/16/2021		A		77180		⁽³⁾	4/16/2023	Common Stock	77180	⁽⁴⁾	77180	D
Stock Option (Right to Buy)	$2.5913	4/16/2021		A		77180		⁽³⁾	4/16/2023	Common Stock	77180	⁽⁵⁾	77180	D
Stock Option (Right to Buy)	$2.5913	4/16/2021		A		96475		⁽³⁾	4/16/2023	Common Stock	96475	⁽⁶⁾	96475	D

Explanation of Responses:
(1)	Received in exchange for 250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
(2)	Received in the Merger in exchange for a stock option to acquire 100,000 shares of common stock of the Former Entity at $1.00 per share.
(3)	These options are fully vested and exercisable.
(4)	Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.
(5)	Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.
(6)	Received in the Merger in exchange for a stock option to acquire 250,000 shares of common stock of the Former Entity at $1.00 per share.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Chapman Christopher C JR 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK,, NY 10036	X		President, Chief Med. Officer